Featured Research

from universities, journals, and other organizations

Tamoxifen Found To Increase Risk Of Endometrial Cancer

Date:
October 8, 1999
Source:
University Of Southern California
Summary:
Women whose breast cancer is treated with tamoxifen face a heightened risk for endometrial cancer, with that risk compounded in women who also have received estrogen replacement therapy or who are obese, according to a study led by University of Southern California researchers.

Women whose breast cancer is treated with tamoxifen face a heightened risk for endometrial cancer, with that risk compounded in women who also have received estrogen replacement therapy or who are obese, according to a study led by University of Southern California researchers.

Leslie Bernstein, Ph.D., professor of preventive medicine at the Keck School of Medicine of the University of Southern California and USC/Norris Comprehensive Cancer Center, and colleagues present these findings in the Oct. 6 issue of the Journal of the National Cancer Institute.

Doctors prescribe tamoxifen, a synthetic hormone, to women as a breast cancer treatment because of its proven benefits for blocking a recurrence of the disease, reducing the likelihood of a second breast cancer developing in the opposite breast and extending patients' survival. It is also under study as a preventive agent against breast cancer in women at high risk for the disease. However, this study indicates the same drug increases the risk of endometrial cancer, the most frequent gynecologic cancer in women.

"Because tamoxifen is a critical therapeutic option for breast cancer patients, we need to understand its other effects on the body," Bernstein said. "Although we have known that endometrial or uterine cancer develops in a tiny proportion of women taking tamoxifen, we have not known which particular groups of women are at greatest risk of this disease."

Overall, the authors report that tamoxifen therapy for breast cancer increased the risk of endometrial cancer by about 50 percent. The longer women are on tamoxifen therapy, the greater their risk: women with more than five years of exposure to tamoxifen were four times more likely to develop endometrial cancer than women who did not use tamoxifen. But a woman's risk of endometrial cancer also varies according to other characteristics.

Factors already known to either increase or decrease women's risk of endometrial cancer include: birth control pills, which reduce risk; estrogen therapy, which can increase risk unless taken in combination with progestin therapy; and obesity, which increases risk. These factors affected the endometrial cancer risk of breast cancer patients in this study.

Tamoxifen increased endometrial cancer risk, primarily among women who had previously used estrogens. The risk of endometrial cancer was more than three times higher among women who had taken both estrogen replacement therapy and tamoxifen than among women who had not taken either drug. And among women who had previously been on estrogen replacement therapy, those who took tamoxifen for more than five years were five and a half times as likely to develop endometrial cancer as women who had not been prescribed tamoxifen.

The risk associated with tamoxifen use was stronger among heavier women than among thinner women, with risk the highest for women who both were overweight and had a history of taking estrogen replacement therapy.

Tamoxifen has been found to have estrogen-like effects on the uterus, which may account for women's increased endometrial cancer risk. Researchers believe obesity may cause greater exposure to estrogen in the uterus, as well.

Endometrial cancer occurs far less frequently than breast cancer, and decisions about whether to prescribe tamoxifen should be considered in light of this differential in risk, Bernstein said. In the United States, recent population statistics show that 110 of every 100,000 women develop breast cancer annually. This is five times greater than the rate of endometrial cancer, which is 21 cases in every 100,000 women. Women also are more likely to die from breast cancer than from endometrial cancer. The chances that a woman will die of breast cancer each year are 26 per every 100,000 women in the United States, far higher than the three per every 100,000 women who die each year of endometrial cancer.

"We have confirmed the findings of other studies showing that tamoxifen increases the risk of uterine cancer; and most importantly, we have found that women who have used estrogens and who are overweight have the greatest risk when

using tamoxifen," Bernstein said. "Our results suggest that physicians should be particularly vigilant in monitoring tamoxifen-treated patients with these additional risk factors."

Bernstein noted that the risk of endometrial cancer must be balanced against tamoxifen's proven benefits in breast cancer treatment and its effectiveness in reducing the incidence of breast cancer among women at high risk for that cancer.

The researchers conducted the study with 324 patients with endometrial cancer who had previously been treated for breast cancer and 671 similar patients with breast cancer who did not develop endometrial cancer.


Story Source:

The above story is based on materials provided by University Of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University Of Southern California. "Tamoxifen Found To Increase Risk Of Endometrial Cancer." ScienceDaily. ScienceDaily, 8 October 1999. <www.sciencedaily.com/releases/1999/10/991008075836.htm>.
University Of Southern California. (1999, October 8). Tamoxifen Found To Increase Risk Of Endometrial Cancer. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/1999/10/991008075836.htm
University Of Southern California. "Tamoxifen Found To Increase Risk Of Endometrial Cancer." ScienceDaily. www.sciencedaily.com/releases/1999/10/991008075836.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins